Advertisements


Darzalex (daratumumab) for sale
Price: | Contact for latest price |
---|---|
Minimum Order: | 10 Boxes |
Payment Terms: | BITCOIN |
Port of Export: | Worldwide |
Product Details
Model No.: | Brand Name: | Darzalex |
---|
Certification: | FDA |
---|---|
Specification: |
Darzalex (daratumumab) for sale
Darzalex (daratumumab) is a medication used for the treatment of multiple myeloma. DARZALEX (DARATUMUMAB) Package Single vial 1 vial of 100 mg/5 mL 1 vial of 400 mg/20 mL |
Packaging & Delivery
Packaging: | DISCREET |
---|---|
Delivery/Lead Time: | 5 DAYS |
Production Capacity: | 100 Boxes |
Product Description
DARZALEX¨ is a prescription medicine used to treat adults with multiple myeloma:
In combination with the medicines lenalidomide and dexamethasone in people with newly diagnosed multiple myeloma who cannot receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant) and in people whose multiple myeloma has come back or did not respond to treatment who have received at least one prior medicine to treat multiple myeloma
In combination with the medicines bortezomib, melphalan, and prednisone in people with newly diagnosed multiple myeloma who cannot receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant)
In combination with the medicines bortezomib, thalidomide, and dexamethasone in newly diagnosed people who are eligible to receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant)
In combination with the medicines bortezomib and dexamethasone in people who have received at least one prior medicine to treat multiple myeloma
In combination with the medicines carfilzomib and dexamethasone in people whose multiple myeloma has come back or did not respond to treatment who have received one to three prior medicines to treat multiple myeloma
In combination with the medicines pomalidomide and dexamethasone in people who have received at least two prior medicines to treat multiple myeloma, including lenalidomide and a proteasome inhibitor
Alone in people who have received at least three prior medicines, including a proteasome inhibitor and an immunomodulatory agent, or did not respond to a proteasome inhibitor and an immunomodulatory agent
SUPPLIER PROFILE
|
|||
---|---|---|---|
Company: | BIOTECH PHARMA | ||
City/State | Miami, FLORIDA | Country: |
United States ![]() |
Business Type: | Export - Manufacturer / Trading Company | Established: | 2009 |
Member Since: | 2021 | Contact Person | Lucas Nolan |
SUPPLIER PROFILE
City/State/Country -
Miami, FLORIDA
United States 

Business Type -
Export - Manufacturer / Trading Company
Established -
2009
Member Since -
2021
Contact Person -
Lucas Nolan